The therapeutic effect of GCs in treating RA is mainly by regulating ligand activated transcription factors, activity of nuclear-receptor, Hsp90 protein-binding, ubiquitin-like protein ligase-binding, and RNA polymerase-II transcription initiation factor-binding. The gene discussed is HSP90AA1; the disease is rheumatoid arthritis.